Candidate: GENOSYL® (nitric oxide) gas with GENOSYL DS delivery system
Type: Inhaled nitric oxide plus tankless delivery system
Status: VERO Biotech said March 24 that the first patient with COVID-19 infection complicating pulmonary hypertension has been treated with GENOSYL via the GENOSYL DS at home, under an emergency IND approved by the FDA. The patient was also treated with oxygen via nasal canula, and monitored remotely by clinicians. Two days later, VERO said the FDA granted the company “expanded access emergency use” allowing GENOSYL DS, to immediately be used for the treatment of cardiopulmonary symptoms associated with COVID-19.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
● ANTIVIRAL
● VAX
● ANTIBODY
● RNA
